| FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $505.67M | ||||
| Company | Location | Date | Amt. (M) | Details |
| Accera Inc. | Broomfield, Colo. | 11/11 | $35 | Accera closed a $35M Series C round led by Inventages Venture Capital SA; it included Posco BioVentures and other previous investors |
| Adimab Inc. | Lebanon, N.H. | 11/20 | ND | Adimab closed a Series C round, with investments from new investors OrbiMed Advisors and Borealis Ventures, as well as Polaris Venture Partners and SV Life Sciences |
| AnaMar Medical AB | Stockholm, Sweden | 11/6 | SEK75 ($9.6) |
AnaMar raised $9.6M in a rights issue guaranteed by the company's principal owner Koncentra Holding AB |
| Arete Therapeutics Inc. | Hayward, Calif. | 11/19 | $16.7 | Arete closed the final tranche of its Series A financing co-led by Frazier Healthcare Ventures and Alta Partners; other investors were Burrill & Co., Three Arch Partners and Altitude Life Science Ventures |
| Ascent Therapeutics Inc. | Cambridge, Mass. | 11/17 | $19 | Ascent raised $19M in a Series A round that was completed in fall 2007, but not announced until November with the appointment of a president and CEO |
| Avantium Technologies BV | Amsterdam, the Netherlands | 11/5** | €18 ($23.4) |
Avantium raised $23.4M in a private financing that will partially be used to buy out existing shareholders, MVM Life Sciences Partners LLP, Signet Healthcare Partners and SR One Ltd. |
| Cellular Dynamics International Inc. | Madison, Wis. | 11/25 | $18 | Cellular Dynamics raised $18M in a Series A round led by Tactics II Stem Cell Ventures LP, with participation from Tactics II Ventures LP and the Wisconsin Alumni Research Foundation |
| Certus Pharmaceuticals Inc. | South San Francisco | 11/6 | ND | Certus received a private equity investment from asset management firm Ascension GmbH |
| Critical Pharmaceuticals | Nottingham, UK | 11/10 | £0.65 ($1) |
Critical Pharmaceuticals closed a third round for $1M; it was fully supported by existing shareholders |
| Ganymed Pharmaceuticals AG | Mainz, Germany | 11/18 | €65 ($82.2) |
Ganymed raised $82.2M in a fourth financing round led by ATS Beteiligungsverwaltung GmbH; Future Capital AG and MIG Verwaltungs AG also participated, along with undisclosed private investors |
| GPC-Rx Corp. | Seattle | 11/21 | ND | GPC-Rx raised an undisclosed amount in a Series A investment led by a syndicate including Alexandria Real Estate Equities, Amgen Ventures, ARCH Ventures Partners, OVP Venture Partners, PPD Inc. and WRF Capital |
| Helion Biotech ApS | Copenhagen, Denmark | 11/11 | ND | Helion Biotech received an undisclosed amount from Danish life science investor group SEED Capital Denmark |
| JADO Technologies GmbH | Dresden, Germany | 11/12** | $4.9 | JADO raised $4.9M in a Series B round |
| Knopp Neurosciences Inc. | Pittsburgh | 11/19 | $6.6 | Knopp completed a $6.6M financing as a result of its current investors exercising Series B2 warrants; investors were Saturn Partners II and Kramer Capital Partners |
| Numerate Inc. | San Bruno, Calif. | 11/18 | $4 | Numerate completed a $4M Series A round, with investments from Foundation Capital, Lanza techVentures and individual investors |
| OncoMed Pharmaceuticals Inc. | Redwood City, Calif. | 11/4 | $154 | OncoMed raised $154M in a Series B round, which included a $93M second tranche completed in November; the rest was brought in in 2006; investors were Adams Street Partners, Nomura Phase4 Ventures, US Venture Partners, latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, DeNovo Ventures and Bay Partners |
| Pharmalink AB | Stockholm, Sweden | 11/14 | SEK8 ($1) |
Pharmalink raised $1M through an issuance of new preferential shares to existing shareholders |
| Precision Therapeutics Inc. | Pittsburgh | 11/10 | $43 | Precision raised $43M in a round led by new investor Longitude Venture Partners LP, with participation from Adams Capital Management, Quaker BioVentures, Birchmere Ventures, Techno Venture Management and Draper Triangle Ventures |
| Prolexys Pharmaceuticals Inc. | Salt Lake City, Utah | 11/5 | $20 | Prolexys raised $20M in a preferred series A1 financing round led and managed by Friedli Corporate Finance AG |
| Psyadon Pharmaceuticals Inc. | Germantown, Md. | 11/10 | $8 | Psyadon received $8M in a financing from New Enterprise Associates |
| Radius Health Inc. | Cambridge, Mass. | 11/20 | $15 | Radius Health raised $15M in a Series C round led by MPM Bio IV NVS Strategic Fund, with participation from MPM Capital, The Wellcome Trust, HealthCare Ventures, Oxford Bioscience Partners, BB Biotech Ventures and Scottish Widows Investment Partnership |
| RCP Therapeutics Ltd. | London | 11/12** | $10 | RCP closed a $10M first round funding and moved its headquarters from California to London |
| Sol Gel Technologies Ltd. | Rehovot, Israel | 11/18 | $9 | Sol Gel completed a $9M investment round led by Medica Venture Partners and including other investors |
| Tengion Inc. | East Norriton, Pa. | 11/19 | $21 | Tengion raised $21M in a second closing of a Series C round that included new investor Safeguard Scientifics Inc. |
| Xentech | Evry, France | 11/12** | $0.765 | Xentech raised seed capital of $765,000 from Aurinvest Capital 2 |
| Zacharon Pharmaceuticals Inc. | San Diego | 11/18 | $3.5 | Zacharon raised $3.5M in a Series A financing from Avalon Ventures LLC |
| Notes: | ||||
| Currency conversions are based on exchange rates at the time of the deal. | ||||
| ** Denotes the date the item ran in BioWorld International. | ||||
| ND = Not disclosed. | ||||
